Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors (DM-CHOC-PEN)
A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System
Sponsor: DEKK-TEC, Inc.
This PHASE2 trial investigates Metastatic Malignant Neoplasm to Brain and Primary Brain Tumors and is currently completed. DEKK-TEC, Inc. leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Oct 2020 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- DEKK-TEC, Inc.
- Detroit Clinical Research Center
- Icahn School of Medicine at Mount Sinai
- National Cancer Institute (NCI)
- Ochsner Health System
- The University of Texas Health Science Center, Houston
- Tulane University
For direct contact, visit the study record on ClinicalTrials.gov .